A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials

被引:163
作者
Leibovich, BC
Cheville, JC
Lohse, CM
Zincke, H
Frank, I
Kwon, ED
Merchan, JR
Blute, ML
机构
[1] Mayo Clin Rochester, Dept Urol, Rochester, MN 55905 USA
[2] Mayo Clin Rochester, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[3] Mayo Clin Rochester, Dept Hlth Sci Res, Rochester, MN 55905 USA
[4] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN 55905 USA
[5] Mayo Clin Rochester, Mayo Med Sch, Rochester, MN 55905 USA
关键词
kidney neoplasms; carcinoma; renal cell; neoplasm metastasis; survival;
D O I
10.1097/01.ju.0000177487.64651.3a
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC). Materials and Methods: We studied 727 patients treated with radical nephrectomy for clear cell RCC from 1970 to 2000 who had distant metastases at nephrectomy (285) or in whom metastases subsequently developed (442). A scoring algorithm to predict cancer specific survival was developed using the regression coefficients from a Cox proportional hazards model. Results: There were 606 deaths from clear cell RCC at a median of 1.0 years (range 0 to 14) following metastatic RCC. Constitutional symptoms at nephrectomy (+2), metastases to the bone (+2) or liver (+4), metastases in multiple simultaneous sites (+2), metastases at nephrectomy (+1) or within 2 years of nephrectomy (+3), complete resection of all metastatic sites (-5), tumor thrombus level I to IV (+3), and the primary pathological features of nuclear grade 4 (+3) and histological tumor necrosis (+2) were significantly associated with death from RCC. All patients started with a score of 0 and points were added or subtracted as indicated in parentheses. Cancer specific survival rates at 1 year were 85.1%, 72.1%, 58.8%, 39.0%, and 25.1%, respectively, for patients with scores of -5 to -1, scores of 0 to 2, scores of 3 to 6, scores of 7 or 8, and scores of 9 or more. Conclusions: This scoring algorithm can be used to predict cancer specific survival for patients with metastatic clear cell RCC.
引用
收藏
页码:1759 / 1763
页数:5
相关论文
共 24 条
[1]   Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases [J].
Amin, MB ;
Amin, MB ;
Tamboli, P ;
Javidan, J ;
Stricker, H ;
Venturina, MD ;
Deshpande, A ;
Menon, M .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) :281-291
[2]   The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus [J].
Blute, ML ;
Leibovich, BC ;
Lohse, CM ;
Cheville, JC ;
Zincke, H .
BJU INTERNATIONAL, 2004, 94 (01) :33-41
[3]   Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma [J].
Cheville, JC ;
Lohse, CM ;
Zincke, H ;
Weaver, AL ;
Blute, ML .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) :612-624
[4]   Sarcomatoid renal cell carcinoma - An examination of underlying histologic subtype and an analysis of associations with patient outcome [J].
Cheville, JC ;
Lohse, CM ;
Zincke, H ;
Weaver, AL ;
Leibovich, BC ;
Frank, I ;
Blute, ML .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (04) :435-441
[5]   An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score [J].
Frank, I ;
Blute, ML ;
Cheville, JC ;
Lohse, CM ;
Weaver, AL ;
Zincke, H .
JOURNAL OF UROLOGY, 2002, 168 (06) :2395-2400
[6]  
Gelb AB, 1997, CANCER-AM CANCER SOC, V80, P981
[7]   Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma [J].
Han, KR ;
Pantuck, AJ ;
Bui, MHT ;
Shvarts, O ;
Freitas, DG ;
Zisman, A ;
Leibovich, BC ;
Dorey, FJ ;
Gitlitz, BJ ;
Figlin, RA ;
Belldegrun, AS .
UROLOGY, 2003, 61 (02) :314-319
[8]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[9]  
2-4
[10]  
Kankuri M, 2001, CANCER-AM CANCER SOC, V92, P761, DOI 10.1002/1097-0142(20010815)92:4<761::AID-CNCR1380>3.0.CO